Active	Status	Sponsor type	Region	Phase	Filter
10 Active 0 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kowacs, Pedro André
SKYWAY, NCT04938427 / 2021-002481-40: A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome	Completed	3	270	Europe, Canada, Japan, US, RoW	Placebo, Soticlestat, TAK-935	Takeda	Lennox Gastaut Syndrome (LGS)	01/24	01/24
SKYLINE, NCT04940624 / 2021-002480-22: A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome	Completed	3	144	Europe, Canada, Japan, US, RoW	Soticlestat, TAK-935, Placebo	Takeda	Dravet Syndrome (DS)	04/24	04/24
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease	Recruiting	3	1200	Europe, Canada, Japan, US, RoW	Remternetug, LY3372993, Placebo	Eli Lilly and Company	Alzheimer's Disease	04/29	10/30
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy	Recruiting	3	102	Europe, Canada, US, RoW	Ampreloxetine, TD-9855, Placebo	Theravance Biopharma	Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy	12/24	01/27
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease	Terminated	3	1027	Europe, Canada, Japan, US, RoW	Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo	Biogen, Biogen Idec Research Limited	Alzheimer's Disease	08/24	08/24
ENDYMION 2, NCT05163314 / 2021-002482-17: A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome	Recruiting	3	400	Europe, Canada, Japan, US, RoW	Soticlestat, TAK-935	Takeda	Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)	05/26	05/26
Alves, Matheus de Paula
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy	Recruiting	3	102	Europe, Canada, US, RoW	Ampreloxetine, TD-9855, Placebo	Theravance Biopharma	Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy	12/24	01/27
Pereira, Gabriela
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy	Recruiting	3	102	Europe, Canada, US, RoW	Ampreloxetine, TD-9855, Placebo	Theravance Biopharma	Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy	12/24	01/27
Becker, Jefferson
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy	Recruiting	3	102	Europe, Canada, US, RoW	Ampreloxetine, TD-9855, Placebo	Theravance Biopharma	Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy	12/24	01/27
Paju, Taivo
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy	Recruiting	3	102	Europe, Canada, US, RoW	Ampreloxetine, TD-9855, Placebo	Theravance Biopharma	Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy	12/24	01/27